Actively Recruiting
Phase 3 Randomized Study of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat Compared to Placebo
Led by Caliway Biopharmaceuticals Co., Ltd. · Updated on 2026-10-19
320
Participants Needed
13
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a phase 3 clinical trial to study adults with moderate or severe abdominal subcutaneous fat. The trial aims to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared to a placebo in reducing abdominal fat. Approximately 320 participants will be enrolled to better understand how well this treatment works and how safe it is for reducing fat under the skin in the abdominal area. Participants will be randomly assigned to receive either the CBL-514 injection or a placebo 0.9% Sodium Chloride solution. Each participant can receive up to four treatments, with injections administered subcutaneously to the abdomen at four-week intervals. Both groups will receive up to 120 mL per treatment, delivered through 50 injections each time. During the study, participants will undergo assessments including patient and clinician reports on abdominal fat levels, measured from the start of the study to four weeks after the final treatment. Researchers will monitor changes in abdominal fat and improvements on rating scales. Participants will also be evaluated for safety and tolerability throughout the trial, which is expected to last until September 2027.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
Research Team
C
Candra Chou
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here